About

IES Life Sciences, Inc.was formed to develop and commercialize, in partnership with the U.S. Food and Drug Administration (“FDA”) via a licensing agreement from the National Institutes of Health, a test kit capable of detecting and measuring the unique combination of Interferons released by a diseased human cell. Once this “Interferon Expression Signature" for a particular disease is identified, it can be used to diagnose a disease, determine its severity and create therapies to treat the disease. Repeat testing of the Interferon Expression Signature will allow physicians to adjust the treatment to optimal levels. This test provides significant benefits to the drug development community while also promising to give patients the highest clinical benefit with the fewest side effects at the lowest cost.